<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03455387</url>
  </required_header>
  <id_info>
    <org_study_id>CHMS16001</org_study_id>
    <nct_id>NCT03455387</nct_id>
  </id_info>
  <brief_title>Evaluation of the Serum Markers sFLt1 and PlGF for the Prediction of the Complications of the Placental Vascular Pathologies in the 3rd Quarter of the Pregnancy.</brief_title>
  <acronym>PRECOPE</acronym>
  <official_title>Evaluation of the Serum Markers sFLt1 and PlGF for the Prediction of the Complications of the Placental Vascular Pathologies in the 3rd Quarter of the Pregnancy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Metropole Savoie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Metropole Savoie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pre-eclampsia is a frequent pathology, concerning approximately 5 % of the
      pregnancies.The pre-eclampsia can evolve into severe maternal and\or foetal complications and
      is a major cause of mortality.

      The purpose of the study will to estimate the relevance of the serum markers sFlt1 and PlGF
      to predict the arisen of severe complications at these patients, what would allow to decrease
      the materno-fœtale morbi-mortality due to the pathology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pre-eclampsia is a frequent pathology, concerning approximately 5 % of the pregnancies.
      It is a major cause of mortality, mainly in the developing country. His incidence tends to
      increase in the developed countries. In the absence of adapted coverage, the pre-eclampsia
      can evolve into severe maternal and\or foetal complications (eclampsia, foetal intra-uterine,
      dead HELLP syndrome, lung acute oedema, stunting in utero).

      The pre-eclampsia is a part of placental vascular pathologies. Several studies showed that
      these pathologies are due to a defect of trophoblastic invasion, secondary in an imbalance in
      the balance of factors pro and antiangiogéniques (PlGF, sFlt1).

      Studies also demonstrated that, for a patient presenting a placental vascular pathology, the
      rate of PlGF is decreased and conversely for the rate of sFlt1. Studies show that the
      duration of the pregnancy, of a patient presenting a placentary vascular pathology, is
      correlated at the rate of these markers.

      There is at present no reliable predictive examination to estimate the arisen of severe
      complications for a patient presenting a placental vascular pathology. The purpose of the
      study will to estimate the relevance of the serum markers sFlt1 and PlGF to predict the
      arisen of severe complications for these patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2017</start_date>
  <completion_date type="Anticipated">April 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 10, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Arisen of a maternal and/or fetal severe complication</measure>
    <time_frame>during the pregnancy from 24 weeks of gestation until delivery</time_frame>
    <description>The severe maternal complication are : placental abruption, HELLP syndrome, Lung acute oedema ; eclampsia, maternal death.
The fetal severe complications are : intrauterine grow retardation, fetal demise.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Pre-Eclampsia</condition>
  <condition>HELLP Syndrome</condition>
  <condition>Fetal Death</condition>
  <condition>Eclampsia</condition>
  <condition>Placental Abruption</condition>
  <condition>Fetal Growth Retardation, Antenatal</condition>
  <arm_group>
    <arm_group_label>sampling of serum marker Flt1 and PIGF</arm_group_label>
    <description>sampling of the serum markers sFlt1 and PlGF , every 3 days,until delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>sampling of the serum marker sFlt1 and PlGF</intervention_name>
    <description>sampling of the serum markers sFlt1 and PlGF , every 3 days,until delivery</description>
    <arm_group_label>sampling of serum marker Flt1 and PIGF</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All pregnant women with a diagnosis of placental vascular disease during the third
        trimester
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pregnant woman with a diagnosis of placental vascular disease (gestational
             hypertension, preeclampsia, IUGR)

        Exclusion Criteria:

          -  patient who refuses the obstetric follow-up
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe DOCHE</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Metropole Savoie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emmanuel Decroisette</last_name>
    <phone>+33456808205</phone>
    <email>emmanuel.decroisette@ch-metropole-savoie.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabienne Prieur</last_name>
    <phone>+33479965999</phone>
    <email>fabienne.prieur@ch-metropole-savoie.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHMetropoleSavoie</name>
      <address>
        <city>Chambéry</city>
        <state>Savoie</state>
        <zip>73000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Decroisette</last_name>
      <phone>+33456808205</phone>
      <email>emmanuel.decroisette@ch-metropole-savoie.fr</email>
    </contact>
    <contact_backup>
      <last_name>Christophe Doche</last_name>
      <email>christophe.doche@ch-metropole-savoie.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Alpes Léman</name>
      <address>
        <city>Contamine-sur-Arve</city>
        <zip>74130</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne DUCLUSAUD</last_name>
      <email>aduclusaud@ch-alpes-leman.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy Genevois</name>
      <address>
        <city>Metz-Tessy</city>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bénédicte Breton</last_name>
      <email>bbreton@ch-annecygenevois.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux du Léman</name>
      <address>
        <city>Thonon-les-Bains</city>
        <zip>74200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain VINCENT-GENOD</last_name>
      <email>a-vincent-genod@ch-hopitauxduleman.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2018</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sFLt1</keyword>
  <keyword>PlGF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Fetal Growth Retardation</mesh_term>
    <mesh_term>Fetal Death</mesh_term>
    <mesh_term>HELLP Syndrome</mesh_term>
    <mesh_term>Abruptio Placentae</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

